Epidemiological evidence and the clinical trial available suggest the beneficial association between insulin use and parameters of sarcopenia [87,95,96], indicating that a possible prescription of exogenous insulin could improve insulin signaling in the skeletal muscle, promote protein synthesis, and protect against the loss of muscle mass among patients with diabetes, especially those with a long duration of diabetes. This evidence concerns the gene INS and sarcopenia.